A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab,Inflammation Research

当前位置： X-MOL 学术 › Inflamm. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
Inflammation Research ( IF 4.8 ) Pub Date : 2023-03-13 , DOI: 10.1007/s00011-023-01715-1
Xiaoyun Jiang ₁ , Jun Ye ₁ , Xia Wu ₁ , Jiang Zhu ₁ , Siji Chen ₁ , Hao Cheng ₁

Affiliation

Background

Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome (HES). Glucocorticoids are preferred for treatment but carry substantial side effect profiles. Symptoms of HED may recur after systemic glucocorticoid tapering. As an interleukin-4 receptor (IL-4Rα) monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), dupilumab might be an efficacious adjuvant therapy for HED.

Method

We report a young male diagnosed with HED who suffered from erythematous papules with pruritus for over five years. Once reducing the dosage of glucocorticoid was, his skin lesions relapsed.

Results

After using dupilumab, the patient’s condition significantly improved with the glucocorticoid dosing decreased successfully.

Conclusion

In conclusion, we report a new application of dupilumab in HED patients, especially with difficulties in reducing the glucocorticoid dose.

中文翻译：

嗜酸性粒细胞增多性皮炎患者应用dupilumab完全康复一例

背景

嗜酸性粒细胞增多性皮炎 (HED) 是嗜酸性粒细胞增多综合征 (HES) 的一种亚型。糖皮质激素是治疗的首选，但具有显着的副作用特征。在全身性糖皮质激素逐渐减量后，HED 的症状可能会复发。作为靶向白细胞介素 4 (IL-4) 和白细胞介素 13 (IL-13) 的白细胞介素 4 受体 (IL-4Rα) 单克隆抗体，dupilumab 可能是 HED 的有效辅助疗法。